Doctors Paid By Drug Companies Tend To Prescribe Their Brand-Name Drugs More: Study

The findings of a new study appear to confirm suspicions that pharmaceutical companies are able to buy off doctors, and get them to prescribe their brand-name medications more often than generic drugs or their competitors.

Doctors who received industry payments were more likely to prescribe the drugs manufactured by the company that paid them, according to researchers with Harvard Medical School and Brigham and Women’s Hospital . The findings were published in this month’s issue of the medical journal JAMA Internal Medicine.

Researchers looked at Part D Medicare prescriptions claims data involving statins, a popular class of cholesterol drugs that includes the blockbuster drugs Lipitor and Crestor, as well as the Massachusetts physicians payment database.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Out of the 2,444 Massachusetts doctors in the database in 2011, 899, or 36.8% received industry payments, in most cases just company sponsored meals. However, once those payments got larger, a discrepancy became apparent.

“For physicians with no industry payments listed, the median brand-name statin prescribing rate was 17.8%,” the researchers report. “For every $1,000 in total payments received, the brand-name statin prescribing rate increased by 0.1%.”

The study also found that payments linked to “educational training” boosted a company’s brand name drug sales by 4.8% with that doctor.

“As the United States seeks to rein in the costs of prescription drugs and make them less expensive for patients, our findings are concerning,” the researchers warned.

Such payments, often referred to as kickbacks, have long been a concern of the medical industry. Critics say that they lead to patients being directed toward more expense brand-name drugs as opposed to equally effective generics, and in some cases are directed to drugs they do not need or which may put them at unnecessary risk of side effects.

In recent years, a number of pharmaceutical companies have been hit with lawsuits from the Department of Justice over such promotional activities.

One of the largest resulted in a Pfizer settlement for $2.3 billion in 2009, after the drug maker was accused of illegal marketing and kickbacks associated with the painkiller Bextra and other drugs. Prosecutors said Pfizer gave doctors illegal incentives that included paying them for weekend meetings in resort locations.

In 2013, C.R. Bard agreed to pay $48.26 million to settle a whistleblower lawsuit which claimed it paid kickbacks to doctors who used its radioactive seeds to treat prostate cancer. The company gave them free medical supplies, grants, rebates, conferencing fees and marketing assistance.

Such kickback schemes are considered a form of Medicare fraud.

Just last year, Daiichi Sankyo agreed to pay $39 million to settle Justice Department charges that it illegally paid kickbacks to doctors who prescribed the hypertension drug Benicar and other medications.

According to the FBI and the U.S. Department of Justice, the kickbacks occurred between January 1, 2004 and March 31, 2011, in the form of honoraria payments, meals and other incentives that occurred as part of its Physician opinion & Discussion program and other programs.

Law enforcement officials say Daiichi Sankyo even paid doctors when they only spoke to their own staff in his or her own office, or even their own spouses. They also paid doctors for speaking engagements that never actually happened, according to the allegations.

Investigators say the company also paid the doctors through lavish meals which even sometimes exceeded the company’s own policy limiting such meals to $140 per person.

In 2009, payments from pharmaceutical companies to doctors was at about $188.86 million. By 2011, that number had jumped to $773.05 million, but much of that increase was attributed to companies being more willing to admit how much they had paid out.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.